Citigroup’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-231,508
| Closed | -$24.7M | – | 6510 |
|
|
2025
Q3 | $24.7M | Buy |
231,508
+226,624
| +4,640% | +$23.7M | 0.01% | 951 |
|
|
2025
Q2 | $462K | Buy |
4,884
+3,217
| +193% | +$238K | ﹤0.01% | 3672 |
|
|
2025
Q1 | $106K | Buy |
1,667
+201
| +14% | +$12K | ﹤0.01% | 4573 |
|
|
2024
Q4 | $68.1K | Buy |
1,466
+185
| +14% | +$6.95K | ﹤0.01% | 4995 |
|
|
2024
Q3 | $36.9K | Sell |
1,281
-196
| -13% | -$4.82K | ﹤0.01% | 5082 |
|
|
2024
Q2 | $21.4K | Buy |
1,477
+1,230
| +498% | +$18K | ﹤0.01% | 4982 |
|
|
2024
Q1 | $3.97K | Sell |
247
-961
| -80% | -$16.6K | ﹤0.01% | 5339 |
|
|
2023
Q4 | $24K | Buy |
1,208
+376
| +45% | +$5.55K | ﹤0.01% | 4912 |
|
|
2023
Q3 | $13.6K | Sell |
832
-298
| -26% | -$5.74K | ﹤0.01% | 4484 |
|
|
2023
Q2 | $23.9K | Buy |
1,130
+407
| +56% | +$8.68K | ﹤0.01% | 4917 |
|
|
2023
Q1 | $14.5K | Sell |
723
-57
| -7% | -$1.23K | ﹤0.01% | 4611 |
|
|
2022
Q4 | $20.4K | Buy |
+780
| New | +$10.4K | ﹤0.01% | 4580 |
|
|
2022
Q2 | – | Sell |
-369,008
| Closed | -$1.84M | – | 6698 |
|
|
2022
Q1 | $1.84M | Buy |
+369,008
| New | +$2.15M | ﹤0.01% | 2431 |
|
|
2021
Q4 | – | Sell |
-495,446
| Closed | -$2.71M | – | 6107 |
|
|
2021
Q3 | $2.71M | Buy |
+495,446
| New | +$2.88M | ﹤0.01% | 2298 |
|
Other funds holding VRNA
Citigroup's VRNA Position: Q4 2025 in Review
Citigroup sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 231,508 shares — an estimated $24.7M sold.
Citigroup first reported a position in VRNA in Q3 2021 and held it in 14 quarters. The position peaked at $24.7M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Citigroup reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Citigroup sold 231,508 Verona Pharma shares in Q4 2025, an estimated $24.7M.
- Citigroup first reported a position in Verona Pharma in Q3 2021 and held it in 14 quarters.
- Citigroup's Verona Pharma position peaked at $24.7M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.